{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-081976","form_type":"8-K","ticker":"NMTC","cik":"0001500198","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","filed_at":"2022-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.879074+00:00","generated_at":"2026-06-21T00:00:54.361265+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NeuroOne reports fiscal Q4 2022 net loss of $1.4M; collaboration revenue jumps to $1.94M","bullets":["Product revenue $69K in Q4 vs $48K prior year; full year $171K vs $178K.","Collaboration revenue $1.94M in Q4 from Zimmer Development Agreement, up from $5K.","Net loss $1.4M in Q4 vs $2.6M prior year; full year net loss $10.0M vs $9.9M.","Cash and short-term investments $11.1M at Sept. 30, 2022, up from $6.9M; no debt outstanding.","Operating expenses $3.3M in Q4 vs $2.6M; R&D $1.4M, SG&A $1.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-081976","json":"https://secwatch.observer/filing/0001213900-22-081976.json","markdown":"https://secwatch.observer/filing/0001213900-22-081976.md","text":"https://secwatch.observer/filing/0001213900-22-081976.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500198/000121390022081976/0001213900-22-081976-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500198/000121390022081976/ea170126-8k_neuroone.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T00:00:54.361265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2149a5087f0421f15ce0307aabd8583ea3585b4a","claim":"NEUROONE MEDICAL TECHNOLOGIES Corp reported fiscal year ended September 30, 2022 results: net income $10.0 million.","evidence_excerpt":"Net loss was $10.0 million for the full year fiscal 2022, compared to a net loss of $9.9 million in fiscal 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1500198/000121390022081976/0001213900-22-081976-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended September 30, 2022"},{"label":"Net income","value":"$10.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b9472f27816f3e302af0804b8708a025142cfc13","claim":"NEUROONE MEDICAL TECHNOLOGIES Corp reported fiscal fourth quarter ended September 30, 2022 results: net income $1.4 million.","evidence_excerpt":"Net loss was $1.4 million for the fourth quarter of fiscal 2022, compared to a net loss of $2.6 million in the prior year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1500198/000121390022081976/0001213900-22-081976-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal fourth quarter ended September 30, 2022"},{"label":"Net income","value":"$1.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}